These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28786346)

  • 1. Neuroprotective Role of Agmatine in Neurological Diseases.
    Xu W; Gao L; Li T; Shao A; Zhang J
    Curr Neuropharmacol; 2018; 16(9):1296-1305. PubMed ID: 28786346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of agmatine in neurodegenerative diseases and epilepsy.
    Moretti M; Matheus FC; de Oliveira PA; Neis VB; Ben J; Walz R; Rodrigues AL; Prediger RD
    Front Biosci (Elite Ed); 2014 Jun; 6(2):341-59. PubMed ID: 24896210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors.
    Barua S; Kim JY; Kim JY; Kim JH; Lee JE
    Neurochem Res; 2019 Apr; 44(4):735-750. PubMed ID: 30610652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of agmatine (decarboxylated l-arginine) against oxidative stress and neuroinflammation in rotenone model of Parkinson's disease.
    El-Sayed EK; Ahmed A; Morsy EE; Nofal S
    Hum Exp Toxicol; 2019 Feb; 38(2):173-184. PubMed ID: 30001633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of agmatine for CNS disorders.
    Neis VB; Rosa PB; Olescowicz G; Rodrigues ALS
    Neurochem Int; 2017 Sep; 108():318-331. PubMed ID: 28522414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective offerings by agmatine.
    Kotagale NR; Taksande BG; Inamdar NN
    Neurotoxicology; 2019 Jul; 73():228-245. PubMed ID: 31063707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by agmatine: Possible involvement of the gut microbiome?
    Saha P; Panda S; Holkar A; Vashishth R; Rana SS; Arumugam M; Ashraf GM; Haque S; Ahmad F
    Ageing Res Rev; 2023 Nov; 91():102056. PubMed ID: 37673131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain.
    Zhu MY; Wang WP; Cai ZW; Regunathan S; Ordway G
    Eur J Neurosci; 2008 Mar; 27(6):1320-32. PubMed ID: 18364017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of agmatine: An in-depth overview.
    Rafi H; Rafiq H; Farhan M
    Neuropeptides; 2024 Jun; 105():102429. PubMed ID: 38608401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agmatine as a potential therapeutic intervention in bipolar depression: the preclinical landscape.
    Watts D; Pfaffenseller B; Wollenhaupt-Aguiar B; Paul Géa L; Cardoso TA; Kapczinski F
    Expert Opin Ther Targets; 2019 Apr; 23(4):327-339. PubMed ID: 30764678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuroprotective role of melatonin in neurological disorders.
    Alghamdi BS
    J Neurosci Res; 2018 Jul; 96(7):1136-1149. PubMed ID: 29498103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agmatine effects on mitochondrial membrane potential and NF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells.
    Condello S; Currò M; Ferlazzo N; Caccamo D; Satriano J; Ientile R
    J Neurochem; 2011 Jan; 116(1):67-75. PubMed ID: 21044082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats.
    Bhutada P; Mundhada Y; Humane V; Rahigude A; Deshmukh P; Latad S; Jain K
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):96-105. PubMed ID: 22300747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in neuroprotection. 23-25 January 2003, Key Biscayne, FL, USA.
    Pitkänen A
    IDrugs; 2003 Mar; 6(3):200-2. PubMed ID: 12838983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agmatine protects against intracerebroventricular streptozotocin-induced water maze memory deficit, hippocampal apoptosis and Akt/GSK3β signaling disruption.
    Moosavi M; Zarifkar AH; Farbood Y; Dianat M; Sarkaki A; Ghasemi R
    Eur J Pharmacol; 2014 Aug; 736():107-14. PubMed ID: 24769303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cannabinoids and leptin in neurological diseases.
    Agar E
    Acta Neurol Scand; 2015 Dec; 132(6):371-80. PubMed ID: 25880465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of agmatine in rats with transient cerebral ischemia using MR imaging and histopathologic evaluation.
    Huang YC; Tzeng WS; Wang CC; Cheng BC; Chang YK; Chen HH; Lin PC; Huang TY; Chuang TJ; Lin JW; Chang CP
    Magn Reson Imaging; 2013 Sep; 31(7):1174-81. PubMed ID: 23642800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agmatine, a potential novel therapeutic strategy for depression.
    Freitas AE; Neis VB; Rodrigues ALS
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1885-1899. PubMed ID: 27836390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agmatine has beneficial effect on harmaline-induced essential tremor in rat.
    Akman Ö; Utkan T; Arıcıoğlu F; Güllü K; Ateş N; Karson A
    Neurosci Lett; 2021 May; 753():135881. PubMed ID: 33838255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.